CEFIXIME (cefixime) by Inpharmus is [see microbiology ( )] . Approved for the treatment of adults, older with uncomplicated urinary tract infections caused by susceptible isolates of escherichia coli, proteus mirabilis and 5 more indications. First approved in 2021.
Drug data last refreshed 18h ago
[see Microbiology ( )] .
Worked on CEFIXIME at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
Cefixime for Alternative Syphilis Treatment
Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions
A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions
Cefixime / Azithromycin pK Study